Are you more likely today to recommend active surveillance for selected patients with low-risk prostate cancer than you were five years ago?

Share this article:

Evidence is accumulating that active surveillance is an appropriate way to manage low-risk prostate cancer in selected men, with curative treatment delayed until it is warranted by indicators of disease progression. This evidence includes data showing that active surveillance does not cause a significant increase in prostate-cancer mortality compared with immediate treatment. In fact, an independent panel of the National Institutes of Health in December 2011 concluded that active surveillance is a viable option that should be offered to patients with low-risk prostate cancer.

Renal & Urology News wants to know how urologists view active surveillance today compared with five years ago. Please take a few moments to answer our latest poll question:


Leave a comment below on why you chose your answer. If your answer doesn't match one of our choices, please let us know why.
Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

Has the proportion of your patients undergoing prostate brachytherapy been declining?

Has the proportion of your patients undergoing prostate ...

Prostate cancer patients undergoing radical prostatectomy increased by double digits while those undergoing brachytherapy decreased.

Are statins a valid approach for preventing contrast-induced nephropathy (CIN)?

Are statins a valid approach for preventing contrast-induced ...

Patients treated with statins have a significant 55% decreased odds of contrast-induced nephropathy.

Are you surprised that targeted therapeutics for metastatic renal cell carcinoma (RCC) have not improved survival?

Are you surprised that targeted therapeutics for metastatic ...

A study found that targeted therapeutic agents for treating metastatic RCC has not led to an improvement in survival rates.